http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 04 Jun 2026 10:09:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Travere+presents+long-term+FILSPARI+data+at+European+kidney+conference/26603817.html <p>Travere Therapeutics (NASDAQ: TVTX) presented extended results from its Phase 3 DUPLEX study of FILSPARI at the European Renal Association Congress. The data showed patients with focal segmental glomerulosclerosis who remained on the drug maintained proteinuria reductions over approximately five years of treatment.</p> <p>In the open-label extension study, 37.5% of patients who continued FILSPARI from the initial trial achieved complete remission at some point during treatment, while 87.5% achieved partial remission. Patients who switched from the control drug irbesartan to FILSPARI showed similar improvements, with 28.9% achieving complete remission and 74.6% achieving partial remission.</p> <p>The DUPLEX study enrolled 371 patients ages 8 http://www.streetinsider.com/FDA/Travere+presents+long-term+FILSPARI+data+at+European+kidney+conference/26603817.html Thu, 04 Jun 2026 10:09:15 -0400 A.50215103 O.09235062 O.28798549 TVTX http://www.streetinsider.com/FDA/Travere+presents+long-term+FILSPARI+data+at+European+kidney+conference/26603817.html <p>Travere Therapeutics (NASDAQ: TVTX) presented extended results from its Phase 3 DUPLEX study of FILSPARI at the European Renal Association Congress. The data showed patients with focal segmental glomerulosclerosis who remained on the drug maintained proteinuria reductions over approximately five years of treatment.</p> <p>In the open-label extension study, 37.5% of patients who continued FILSPARI from the initial trial achieved complete remission at some point during treatment, while 87.5% achieved partial remission. Patients who switched from the control drug irbesartan to FILSPARI showed similar improvements, with 28.9% achieving complete remission and 74.6% achieving partial remission.</p> <p>The DUPLEX study enrolled 371 patients ages 8 http://www.streetinsider.com/FDA/Travere+presents+long-term+FILSPARI+data+at+European+kidney+conference/26603817.html Thu, 04 Jun 2026 10:09:15 -0400 A.50215103 O.09235062 O.28798549 TVTX http://www.streetinsider.com/FDA/Travere+presents+long-term+FILSPARI+data+at+European+kidney+conference/26603817.html <p>Travere Therapeutics (NASDAQ: TVTX) presented extended results from its Phase 3 DUPLEX study of FILSPARI at the European Renal Association Congress. The data showed patients with focal segmental glomerulosclerosis who remained on the drug maintained proteinuria reductions over approximately five years of treatment.</p> <p>In the open-label extension study, 37.5% of patients who continued FILSPARI from the initial trial achieved complete remission at some point during treatment, while 87.5% achieved partial remission. Patients who switched from the control drug irbesartan to FILSPARI showed similar improvements, with 28.9% achieving complete remission and 74.6% achieving partial remission.</p> <p>The DUPLEX study enrolled 371 patients ages 8 http://www.streetinsider.com/FDA/Travere+presents+long-term+FILSPARI+data+at+European+kidney+conference/26603817.html Thu, 04 Jun 2026 10:09:15 -0400 A.50215103 O.09235062 O.28798549 TVTX http://www.streetinsider.com/FDA/Travere+presents+long-term+FILSPARI+data+at+European+kidney+conference/26603817.html <p>Travere Therapeutics (NASDAQ: TVTX) presented extended results from its Phase 3 DUPLEX study of FILSPARI at the European Renal Association Congress. The data showed patients with focal segmental glomerulosclerosis who remained on the drug maintained proteinuria reductions over approximately five years of treatment.</p> <p>In the open-label extension study, 37.5% of patients who continued FILSPARI from the initial trial achieved complete remission at some point during treatment, while 87.5% achieved partial remission. Patients who switched from the control drug irbesartan to FILSPARI showed similar improvements, with 28.9% achieving complete remission and 74.6% achieving partial remission.</p> <p>The DUPLEX study enrolled 371 patients ages 8 http://www.streetinsider.com/FDA/Travere+presents+long-term+FILSPARI+data+at+European+kidney+conference/26603817.html Thu, 04 Jun 2026 10:09:15 -0400 A.50215103 O.09235062 O.28798549 TVTX http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html <p class="bwalignc"> <i>Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds over time</i> </p><p class="bwalignc"> <i>Patients who transitioned from active control maximum labeled dose irbesartan to FILSPARI after the double-blind study period demonstrated rapid and sustained reductions in proteinuria</i> </p><p class="bwalignc"> <i>FILSPARI was generally well tolerated for up to five years of follow-up in the study</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html Thu, 04 Jun 2026 10:09:00 -0400 A.50215103 O.09235062 O.28798549 TVTX http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html <p class="bwalignc"> <i>Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds over time</i> </p><p class="bwalignc"> <i>Patients who transitioned from active control maximum labeled dose irbesartan to FILSPARI after the double-blind study period demonstrated rapid and sustained reductions in proteinuria</i> </p><p class="bwalignc"> <i>FILSPARI was generally well tolerated for up to five years of follow-up in the study</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html Thu, 04 Jun 2026 10:09:00 -0400 A.50215103 O.09235062 O.28798549 TVTX http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html <p class="bwalignc"> <i>Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds over time</i> </p><p class="bwalignc"> <i>Patients who transitioned from active control maximum labeled dose irbesartan to FILSPARI after the double-blind study period demonstrated rapid and sustained reductions in proteinuria</i> </p><p class="bwalignc"> <i>FILSPARI was generally well tolerated for up to five years of follow-up in the study</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html Thu, 04 Jun 2026 10:09:00 -0400 A.50215103 O.09235062 O.28798549 TVTX http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html <p class="bwalignc"> <i>Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds over time</i> </p><p class="bwalignc"> <i>Patients who transitioned from active control maximum labeled dose irbesartan to FILSPARI after the double-blind study period demonstrated rapid and sustained reductions in proteinuria</i> </p><p class="bwalignc"> <i>FILSPARI was generally well tolerated for up to five years of follow-up in the study</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html Thu, 04 Jun 2026 10:09:00 -0400 A.50215103 O.09235062 O.28798549 TVTX http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html <p class="bwalignc"> <i>Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds over time</i> </p><p class="bwalignc"> <i>Patients who transitioned from active control maximum labeled dose irbesartan to FILSPARI after the double-blind study period demonstrated rapid and sustained reductions in proteinuria</i> </p><p class="bwalignc"> <i>FILSPARI was generally well tolerated for up to five years of follow-up in the study</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html Thu, 04 Jun 2026 10:09:00 -0400 A.50215103 O.09235062 O.28798549 TVTX http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html <p class="bwalignc"> <i>Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds over time</i> </p><p class="bwalignc"> <i>Patients who transitioned from active control maximum labeled dose irbesartan to FILSPARI after the double-blind study period demonstrated rapid and sustained reductions in proteinuria</i> </p><p class="bwalignc"> <i>FILSPARI was generally well tolerated for up to five years of follow-up in the study</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html Thu, 04 Jun 2026 10:09:00 -0400 A.50215103 O.09235062 O.28798549 TVTX http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html <p class="bwalignc"> <i>Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds over time</i> </p><p class="bwalignc"> <i>Patients who transitioned from active control maximum labeled dose irbesartan to FILSPARI after the double-blind study period demonstrated rapid and sustained reductions in proteinuria</i> </p><p class="bwalignc"> <i>FILSPARI was generally well tolerated for up to five years of follow-up in the study</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html Thu, 04 Jun 2026 10:09:00 -0400 A.50215103 O.09235062 O.28798549 TVTX http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html <p class="bwalignc"> <i>Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds over time</i> </p><p class="bwalignc"> <i>Patients who transitioned from active control maximum labeled dose irbesartan to FILSPARI after the double-blind study period demonstrated rapid and sustained reductions in proteinuria</i> </p><p class="bwalignc"> <i>FILSPARI was generally well tolerated for up to five years of follow-up in the study</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Presents+Long-Term+Open-Label+Extension+Data+from+the+Phase+3+DUPLEX+Study+at+the+63rd+European+Renal+Association+%28ERA%29+2026+Congress/26603813.html Thu, 04 Jun 2026 10:09:00 -0400 A.50215103 O.09235062 O.28798549 TVTX http://www.streetinsider.com/Analyst+PT+Change/Travere+Therapeutics+%28TVTX%29+PT+Raised+to+%2462+at+Citi/26597788.html <p>Citi analyst Yigal Nochomovitz raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $62.00 (from $59.00) while maintaining a Buy rating.</p> http://www.streetinsider.com/Analyst+PT+Change/Travere+Therapeutics+%28TVTX%29+PT+Raised+to+%2462+at+Citi/26597788.html Wed, 03 Jun 2026 12:53:31 -0400 TVTX http://www.streetinsider.com/Analyst+PT+Change/Travere+Therapeutics+%28TVTX%29+PT+Raised+to+%2467+at+H.C.+Wainwright/26589837.html <p>H.C. Wainwright analyst Joseph Pantginis raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $67.00 (from $57.00) while maintaining a Buy rating.</p><p>The analyst comments "We reiterate our Buy rating and are increasing our price target to $67 from $57 based on the addition of civerobrutinib to our overall valuation, but just for the PMN indication. We see potential upside from the inclusion of additional indications. Our valuation of Travere is now split into two components. First regarding current sales of FILSPARI, our valuation is based on a risk-adjusted net present value (rNPV) analysis of projected future revenues; we assume http://www.streetinsider.com/Analyst+PT+Change/Travere+Therapeutics+%28TVTX%29+PT+Raised+to+%2467+at+H.C.+Wainwright/26589837.html Tue, 02 Jun 2026 11:38:13 -0400 TVTX http://www.streetinsider.com/Analyst+Comments/Travere+Therapeutics+%28TVTX%29+PT+Raised+to+%2467+at+H.C.+Wainwright/26589837.html <p>H.C. Wainwright analyst Joseph Pantginis raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $67.00 (from $57.00) while maintaining a Buy rating.</p><p>The analyst comments "We reiterate our Buy rating and are increasing our price target to $67 from $57 based on the addition of civerobrutinib to our overall valuation, but just for the PMN indication. We see potential upside from the inclusion of additional indications. Our valuation of Travere is now split into two components. First regarding current sales of FILSPARI, our valuation is based on a risk-adjusted net present value (rNPV) analysis of projected future revenues; we assume http://www.streetinsider.com/Analyst+Comments/Travere+Therapeutics+%28TVTX%29+PT+Raised+to+%2467+at+H.C.+Wainwright/26589837.html Tue, 02 Jun 2026 11:38:13 -0400 TVTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Travere+Therapeutics%2C+++++For%3A+Jun+01/26587298.html si-local-file:///var/storage/secattach/20260602/26587298.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Travere+Therapeutics%2C+++++For%3A+Jun+01/26587298.html Tue, 02 Jun 2026 07:05:00 -0400 O.09235062 TVTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Travere+Therapeutics%2C+++++For%3A+Jun+01/26587298.html si-local-file:///var/storage/secattach/20260602/26587298.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Travere+Therapeutics%2C+++++For%3A+Jun+01/26587298.html Tue, 02 Jun 2026 07:05:00 -0400 O.09235062 TVTX http://www.streetinsider.com/Corporate+News/Travere+licenses+BTK+inhibitor+from+Everest+for+rare+kidney+diseases/26587241.html <p>Travere Therapeutics Inc. (NASDAQ: TVTX) entered into an exclusive licensing agreement with Everest Medicines for civorebrutinib, an investigational oral BTK inhibitor for rare kidney diseases in markets outside China and certain East and Southeast Asian countries.</p><p>Under the agreement, Everest will receive an upfront payment of $112.5 million and is eligible for up to approximately $1.03 billion in additional milestone payments across up to five indications. Travere will pay tiered royalties on future sales ranging from high single-digit to double-digit percentages based on annual net sales thresholds.</p><p>Civorebrutinib is a covalent reversible Bruton's tyrosine kinase inhibitor designed for immune-mediated kidney diseases. The http://www.streetinsider.com/Corporate+News/Travere+licenses+BTK+inhibitor+from+Everest+for+rare+kidney+diseases/26587241.html Tue, 02 Jun 2026 07:01:35 -0400 TVTX http://www.streetinsider.com/FDA/Travere+licenses+BTK+inhibitor+from+Everest+for+rare+kidney+diseases/26587241.html <p>Travere Therapeutics Inc. (NASDAQ: TVTX) entered into an exclusive licensing agreement with Everest Medicines for civorebrutinib, an investigational oral BTK inhibitor for rare kidney diseases in markets outside China and certain East and Southeast Asian countries.</p><p>Under the agreement, Everest will receive an upfront payment of $112.5 million and is eligible for up to approximately $1.03 billion in additional milestone payments across up to five indications. Travere will pay tiered royalties on future sales ranging from high single-digit to double-digit percentages based on annual net sales thresholds.</p><p>Civorebrutinib is a covalent reversible Bruton's tyrosine kinase inhibitor designed for immune-mediated kidney diseases. The http://www.streetinsider.com/FDA/Travere+licenses+BTK+inhibitor+from+Everest+for+rare+kidney+diseases/26587241.html Tue, 02 Jun 2026 07:01:35 -0400 TVTX http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Enters+Into+Exclusive+Licensing+Agreement+with+Everest+Medicines+for+Civorebrutinib+a+Potential+Best-in-Class+BTK+Inhibitor+for+Rare+Kidney+Diseases/26587232.html <p class="bwalignc"> <i>Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases</i> </p><p class="bwalignc"> <i>Civorebrutinib adds pipeline-in-a-product potential across multiple rare kidney diseases, expanding and diversifying Travere’s pipeline</i> </p><p class="bwalignc"> <i>Company to host conference call June 2, 2026 at 8:30 a.m. ET</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Enters+Into+Exclusive+Licensing+Agreement+with+Everest+Medicines+for+Civorebrutinib+a+Potential+Best-in-Class+BTK+Inhibitor+for+Rare+Kidney+Diseases/26587232.html Tue, 02 Jun 2026 07:01:00 -0400 O.09235062 TVTX http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Enters+Into+Exclusive+Licensing+Agreement+with+Everest+Medicines+for+Civorebrutinib+a+Potential+Best-in-Class+BTK+Inhibitor+for+Rare+Kidney+Diseases/26587232.html <p class="bwalignc"> <i>Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases</i> </p><p class="bwalignc"> <i>Civorebrutinib adds pipeline-in-a-product potential across multiple rare kidney diseases, expanding and diversifying Travere’s pipeline</i> </p><p class="bwalignc"> <i>Company to host conference call June 2, 2026 at 8:30 a.m. ET</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside http://www.streetinsider.com/Press+Releases/Travere+Therapeutics+Enters+Into+Exclusive+Licensing+Agreement+with+Everest+Medicines+for+Civorebrutinib+a+Potential+Best-in-Class+BTK+Inhibitor+for+Rare+Kidney+Diseases/26587232.html Tue, 02 Jun 2026 07:01:00 -0400 O.09235062 TVTX http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Enters+Into+Exclusive+Licensing+Agreement+with+Everest+Medicines+for+Civorebrutinib+a+Potential+Best-in-Class+BTK+Inhibitor+for+Rare+Kidney+Diseases/26587232.html <p class="bwalignc"> <i>Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases</i> </p><p class="bwalignc"> <i>Civorebrutinib adds pipeline-in-a-product potential across multiple rare kidney diseases, expanding and diversifying Travere’s pipeline</i> </p><p class="bwalignc"> <i>Company to host conference call June 2, 2026 at 8:30 a.m. ET</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Enters+Into+Exclusive+Licensing+Agreement+with+Everest+Medicines+for+Civorebrutinib+a+Potential+Best-in-Class+BTK+Inhibitor+for+Rare+Kidney+Diseases/26587232.html Tue, 02 Jun 2026 07:01:00 -0400 O.09235062 TVTX http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Enters+Into+Exclusive+Licensing+Agreement+with+Everest+Medicines+for+Civorebrutinib+a+Potential+Best-in-Class+BTK+Inhibitor+for+Rare+Kidney+Diseases/26587232.html <p class="bwalignc"> <i>Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases</i> </p><p class="bwalignc"> <i>Civorebrutinib adds pipeline-in-a-product potential across multiple rare kidney diseases, expanding and diversifying Travere’s pipeline</i> </p><p class="bwalignc"> <i>Company to host conference call June 2, 2026 at 8:30 a.m. ET</i> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside http://www.streetinsider.com/Business+Wire/Travere+Therapeutics+Enters+Into+Exclusive+Licensing+Agreement+with+Everest+Medicines+for+Civorebrutinib+a+Potential+Best-in-Class+BTK+Inhibitor+for+Rare+Kidney+Diseases/26587232.html Tue, 02 Jun 2026 07:01:00 -0400 O.09235062 TVTX http://www.streetinsider.com/Corporate+News/Travere+receives+patent+allowance+for+FILSPARI+use+in+kidney+disease/26557744.html <p>Travere Therapeutics Inc. (NASDAQ: TVTX) received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 19/253,088, which covers certain methods of using FILSPARI (sparsentan) in IgA nephropathy treatment.</p> <p>The patent application, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," is expected to provide U.S. patent coverage for specific methods of using sparsentan in IgA nephropathy until October 2037, according to the company's statement.</p> <p>The application will become a U.S. patent following payment of the issue fee and standard USPTO post-allowance processing. Travere plans to submit the issued patent for listing in http://www.streetinsider.com/Corporate+News/Travere+receives+patent+allowance+for+FILSPARI+use+in+kidney+disease/26557744.html Wed, 27 May 2026 16:05:15 -0400 O.09235062 TVTX http://www.streetinsider.com/Corporate+News/Travere+receives+patent+allowance+for+FILSPARI+use+in+kidney+disease/26557744.html <p>Travere Therapeutics Inc. (NASDAQ: TVTX) received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 19/253,088, which covers certain methods of using FILSPARI (sparsentan) in IgA nephropathy treatment.</p> <p>The patent application, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," is expected to provide U.S. patent coverage for specific methods of using sparsentan in IgA nephropathy until October 2037, according to the company's statement.</p> <p>The application will become a U.S. patent following payment of the issue fee and standard USPTO post-allowance processing. Travere plans to submit the issued patent for listing in http://www.streetinsider.com/Corporate+News/Travere+receives+patent+allowance+for+FILSPARI+use+in+kidney+disease/26557744.html Wed, 27 May 2026 16:05:15 -0400 O.09235062 TVTX